Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 337

1.

Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease.

Ritter C, Miller B, Coyne DW, Gupta D, Zheng S, Brown AJ, Slatopolsky E.

Kidney Int. 2017 Nov;92(5):1217-1222. doi: 10.1016/j.kint.2017.05.003. Epub 2017 Jul 24.

PMID:
28750928
2.

Phosphate Toxicity in CKD: The Killer among Us.

Ritter CS, Slatopolsky E.

Clin J Am Soc Nephrol. 2016 Jun 6;11(6):1088-100. doi: 10.2215/CJN.11901115. Epub 2016 Feb 10. Review.

3.

Differential expression and regulation of Klotho by paricalcitol in the kidney, parathyroid, and aorta of uremic rats.

Ritter CS, Zhang S, Delmez J, Finch JL, Slatopolsky E.

Kidney Int. 2015 Jun;87(6):1141-52. doi: 10.1038/ki.2015.22. Epub 2015 Feb 18.

4.

Cardiac and renal effects of atrasentan in combination with enalapril and paricalcitol in uremic rats.

Ritter C, Zhang S, Finch JL, Liapis H, Suarez E, Ferder L, Delmez J, Slatopolsky E.

Kidney Blood Press Res. 2014;39(4):340-52. doi: 10.1159/000355811. Epub 2014 Sep 19.

5.

Targeting parathyroid hormone levels in dialysis patients.

Saab G, Navaneethan SD, Slatopolsky E.

Semin Dial. 2014 Nov-Dec;27(6):562-5. doi: 10.1111/sdi.12275. Epub 2014 Jul 8. No abstract available.

PMID:
25040125
6.

Should monitoring of fibroblast growth factor-23 levels in dialysis patients be a part of routine clinical practice?

Saab G, Lam M, Navaneethan SD, Slatopolsky E.

Semin Dial. 2014 Nov-Dec;27(6):565-8. doi: 10.1111/sdi.12274. Epub 2014 Jul 8. Review. No abstract available.

PMID:
25040017
7.

Phosphate restriction significantly reduces mortality in uremic rats with established vascular calcification.

Finch JL, Lee DH, Liapis H, Ritter C, Zhang S, Suarez E, Ferder L, Slatopolsky E.

Kidney Int. 2013 Dec;84(6):1145-53. doi: 10.1038/ki.2013.213. Epub 2013 Oct 9.

8.

Clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of mineral and bone disorders in chronic kidney disease (CKD-MBD) in adults.

Bellorin-Font E, Ambrosoni P, Carlini RG, Carvalho AB, Correa-Rotter R, Cueto-Manzano A, Jara A, Jorgetti V, Negri AL, Olaizola I, Salusky I, Slatopolsky E, Weisinger JR; Comité de Metabolismo Mineral y Óseo; Sociedad Latinoamericana de Nefrología e Hipertensión (SLANH).

Nefrologia. 2013;33 Suppl 1:1-28. doi: 10.3265/Nefrologia.pre2013.Feb.11945. English, Spanish. Erratum in: Nefrologia. 2013 Nov 13;33(6):868. Negri, Armando [corrected to Negri, Armando L].

9.

Vitamin D therapy and cardiac function in chronic kidney disease.

Slatopolsky E.

JAMA. 2012 Jun 6;307(21):2254; author reply 2254-5. doi: 10.1001/jama.2012.4172. No abstract available.

PMID:
22706822
10.

FGF23 and PTH--double agents at the heart of CKD.

Silver J, Rodriguez M, Slatopolsky E.

Nephrol Dial Transplant. 2012 May;27(5):1715-20. doi: 10.1093/ndt/gfs050. Epub 2012 Mar 23. Review. No abstract available.

11.

Effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats.

Finch JL, Suarez EB, Husain K, Ferder L, Cardema MC, Glenn DJ, Gardner DG, Liapis H, Slatopolsky E.

Am J Physiol Renal Physiol. 2012 Jan 1;302(1):F141-9. doi: 10.1152/ajprenal.00293.2011. Epub 2011 Sep 28.

12.
13.

50 Years of Research and Discovery in Chronic Kidney Disease and Mineral & Bone Disorder: The Central Role of Phosphate.

Slatopolsky E, Moe S.

Kidney Int. 2011 Apr;79121:S1-2. doi: 10.1038/ki.2011.22. No abstract available.

14.

The intact nephron hypothesis: the concept and its implications for phosphate management in CKD-related mineral and bone disorder.

Slatopolsky E.

Kidney Int Suppl. 2011 Apr;(121):S3-8. doi: 10.1038/ki.2011.23. Epub 2011 Feb 23. Review.

15.

50 years of research and discovery in chronic kidney disease and mineral & bone disorder: the central role of phosphate.

Slatopolsky E, Moe S.

Kidney Int Suppl. 2011 Apr;(121):S1-2. doi: 10.1038/ki.2011.22. Epub 2011 Feb 23. No abstract available.

16.

Effects of sodium thiosulfate on vascular calcification in end-stage renal disease: a pilot study of feasibility, safety and efficacy.

Mathews SJ, de Las Fuentes L, Podaralla P, Cabellon A, Zheng S, Bierhals A, Spence K, Slatopolsky E, Davila-Roman VG, Delmez JA.

Am J Nephrol. 2011;33(2):131-8. doi: 10.1159/000323550. Epub 2011 Jan 17.

17.

Dr. Saulo Klahr, 1935-2010.

Slatopolsky EA.

Kidney Int. 2010 Sep;78(6):529-30. doi: 10.1038/ki.2010.255. No abstract available.

18.

Myocardial effects of VDR activators in renal failure.

Mizobuchi M, Nakamura H, Tokumoto M, Finch J, Morrissey J, Liapis H, Slatopolsky E.

J Steroid Biochem Mol Biol. 2010 Jul;121(1-2):188-92. doi: 10.1016/j.jsbmb.2010.03.026. Epub 2010 Mar 15.

19.

Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease.

Finch JL, Tokumoto M, Nakamura H, Yao W, Shahnazari M, Lane N, Slatopolsky E.

Am J Physiol Renal Physiol. 2010 Jun;298(6):F1315-22. doi: 10.1152/ajprenal.00552.2009. Epub 2010 Mar 3.

20.

Novel markers of left ventricular hypertrophy in uremia.

Nakamura H, Tokumoto M, Mizobuchi M, Ritter CS, Finch JL, Mukai M, Slatopolsky E.

Am J Nephrol. 2010;31(4):292-302. doi: 10.1159/000279768. Epub 2010 Jan 30.

21.

Vascular calcification: the killer of patients with chronic kidney disease.

Mizobuchi M, Towler D, Slatopolsky E.

J Am Soc Nephrol. 2009 Jul;20(7):1453-64. doi: 10.1681/ASN.2008070692. Epub 2009 May 28.

22.

Calcium-sensing receptor expression is regulated by glial cells missing-2 in human parathyroid cells.

Mizobuchi M, Ritter CS, Krits I, Slatopolsky E, Sicard G, Brown AJ.

J Bone Miner Res. 2009 Jul;24(7):1173-9. doi: 10.1359/jbmr.090211.

23.

Blockage of the renin-angiotensin system attenuates mortality but not vascular calcification in uremic rats: sevelamer carbonate prevents vascular calcification.

Tokumoto M, Mizobuchi M, Finch JL, Nakamura H, Martin DR, Slatopolsky E.

Am J Nephrol. 2009;29(6):582-91. doi: 10.1159/000192844. Epub 2009 Jan 15.

PMID:
19145073
24.

Relation of serum fetuin-A levels to coronary artery calcium in African-American patients on chronic hemodialysis.

Zheng S, de Las Fuentes L, Bierhals A, Ash-Bernal R, Spence K, Slatopolsky E, Davila-Roman VG, Delmez J.

Am J Cardiol. 2009 Jan 1;103(1):46-9. doi: 10.1016/j.amjcard.2008.08.032. Epub 2008 Oct 30.

25.

Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats.

Husain K, Ferder L, Mizobuchi M, Finch J, Slatopolsky E.

Am J Nephrol. 2009;29(5):465-72. doi: 10.1159/000178251. Epub 2008 Nov 26.

PMID:
19033720
26.

Activator protein 2alpha mediates parathyroid TGF-alpha self-induction in secondary hyperparathyroidism.

Arcidiacono MV, Cozzolino M, Spiegel N, Tokumoto M, Yang J, Lu Y, Sato T, Lomonte C, Basile C, Slatopolsky E, Dusso AS.

J Am Soc Nephrol. 2008 Oct;19(10):1919-28. doi: 10.1681/ASN.2007111216. Epub 2008 Jun 25.

27.

Vitamin D analogs: therapeutic applications and mechanisms for selectivity.

Brown AJ, Slatopolsky E.

Mol Aspects Med. 2008 Dec;29(6):433-52. doi: 10.1016/j.mam.2008.04.001. Epub 2008 May 1. Review.

PMID:
18554710
28.

Clinical consequences and management of hypomagnesemia.

Martin KJ, González EA, Slatopolsky E.

J Am Soc Nephrol. 2009 Nov;20(11):2291-5. doi: 10.1681/ASN.2007111194. Epub 2008 Jan 30.

29.

EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease.

Arcidiacono MV, Sato T, Alvarez-Hernandez D, Yang J, Tokumoto M, Gonzalez-Suarez I, Lu Y, Tominaga Y, Cannata-Andia J, Slatopolsky E, Dusso AS.

J Am Soc Nephrol. 2008 Feb;19(2):310-20. doi: 10.1681/ASN.2007040406. Epub 2008 Jan 23.

30.
31.

Differential effects of vitamin D receptor activators on vascular calcification in uremic rats.

Mizobuchi M, Finch JL, Martin DR, Slatopolsky E.

Kidney Int. 2007 Sep;72(6):709-15. Epub 2007 Jun 27.

32.

Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats.

Mizobuchi M, Morrissey J, Finch JL, Martin DR, Liapis H, Akizawa T, Slatopolsky E.

J Am Soc Nephrol. 2007 Jun;18(6):1796-806. Epub 2007 May 18.

33.

Effect of 2-methylene-19-nor-(20S)-1 alpha-hydroxy-bishomopregnacalciferol (2MbisP), an analog of vitamin D, on secondary hyperparathyroidism.

Slatopolsky E, Finch JL, Brown AJ, Ritter CS, Mizobuchi M, Plum LA, Clagett-Dame M, Sicinski RR, DeLuca HF.

J Bone Miner Res. 2007 May;22(5):686-94.

34.

Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.

Brown AJ, Slatopolsky E.

Nat Clin Pract Endocrinol Metab. 2007 Feb;3(2):134-44. Review.

PMID:
17237840
35.

Molecular basis of parathyroid hyperplasia.

Dusso AS, Arcidiacono MV, Sato T, Alvarez-Hernandez D, Yang J, Gonzalez-Suarez I, Tominaga Y, Slatopolsky E.

J Ren Nutr. 2007 Jan;17(1):45-7. Review. No abstract available.

PMID:
17198931
36.

Pathogenic mechanisms for parathyroid hyperplasia.

Dusso AS, Sato T, Arcidiacono MV, Alvarez-Hernandez D, Yang J, Gonzalez-Suarez I, Tominaga Y, Slatopolsky E.

Kidney Int Suppl. 2006 Jul;(102):S8-11.

PMID:
16810310
37.

25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells.

Ritter CS, Armbrecht HJ, Slatopolsky E, Brown AJ.

Kidney Int. 2006 Aug;70(4):654-9. Erratum in: Kidney Int. 2006 Sep;70(6):1190.

38.

Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients.

Joist HE, Ahya SN, Giles K, Norwood K, Slatopolsky E, Coyne DW.

Clin Nephrol. 2006 May;65(5):335-41.

PMID:
16724654
39.

Progressive accumulation of lanthanum in the liver of normal and uremic rats.

Slatopolsky E, Liapis H, Finch J.

Kidney Int. 2005 Dec;68(6):2809-13.

40.

Pathogenesis of vascular calcification in chronic kidney disease.

Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E.

Kidney Int. 2005 Aug;68(2):429-36. Review.

41.

A critical role for enhanced TGF-alpha and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease.

Cozzolino M, Lu Y, Sato T, Yang J, Suarez IG, Brancaccio D, Slatopolsky E, Dusso AS.

Am J Physiol Renal Physiol. 2005 Nov;289(5):F1096-102. Epub 2005 Jul 5.

42.

Vitamin D.

Dusso AS, Brown AJ, Slatopolsky E.

Am J Physiol Renal Physiol. 2005 Jul;289(1):F8-28. Review.

43.

Acute regulation of parathyroid hormone by dietary phosphate.

Martin DR, Ritter CS, Slatopolsky E, Brown AJ.

Am J Physiol Endocrinol Metab. 2005 Oct;289(4):E729-34. Epub 2005 May 24.

44.

Calcium, phosphorus and vitamin D disorders in uremia.

Slatopolsky E, Brown A, Dusso A.

Contrib Nephrol. 2005;149:261-71. Review.

PMID:
15876849
45.

[Effects of intravenous and oral OCT on secondary hyperparathyroidism in dogs with chronic renal failure].

Takahashi F, Yorozu K, Kawata Y, Kitamura H, Chiba N, Kubodera N, Slatopolsky E.

Clin Calcium. 2002 Jun;12(6):741-8. Japanese.

PMID:
15775360
46.

[Renal failure and vitamin D].

Brown AJ, Dusso AS, Slatopolsky E.

Clin Calcium. 2002 Jun;12(6):711-23. Japanese.

PMID:
15775356
47.

Pathogenesis of parathyroid hyperplasia in renal failure.

Cozzolino M, Brancaccio D, Gallieni M, Galassi A, Slatopolsky E, Dusso A.

J Nephrol. 2005 Jan-Feb;18(1):5-8.

PMID:
15772917
48.

Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism.

Akizawa T, Ohashi Y, Akiba T, Suzuki M, Nishizawa Y, Ogata E, Slatopolsky E, Kurokawa K.

Ther Apher Dial. 2004 Dec;8(6):480-91.

PMID:
15663548
49.
50.

Supplemental Content

Loading ...
Support Center